Source:http://linkedlifedata.com/resource/pubmed/id/17400422
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
2007-8-27
|
| pubmed:abstractText |
Isolated hepatic perfusion (IHP) offers the advantage of high local drug exposure with limited systemic toxicity. To increase local drug exposure, we administered melphalan at a reduced flow in the hepatic artery during IHP (hepatic artery infusion, hepatic artery-portal vein perfusion, HI-HPP). Between December 2001 and December 2004, 30 patients with colorectal cancer liver metastases underwent HI-HPP with 200mg melphalan. Samples of the perfusate were taken for pharmacokinetic analysis. Patients were monitored for response, toxicity and survival. Perfusion was aborted prematurely in 2 patients due to leakage. During melphalan administration in the hepatic inflow cannula a mean flow rate of 121.3 mL/min and mean pressure of 62.5mm Hg were achieved. One patient died within 30 days after HI-HPP. Four patients developed veno-occlusive disease (VOD), while 2 patients showed signs of VOD. Twelve patients showed hepatic response, with a median duration of response of 11.5 months, according to WHO criteria. Although HI-HPP results in high perfusate melphalan concentration levels, it is associated with a relatively high level of hepatotoxicity and a limited response rate. We believe that the low flow and pressure rates found in this study can result in reduced drug penetration of the tumour and thus limited tumour response.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0748-7983
|
| pubmed:author |
pubmed-author:GelderblomHH,
pubmed-author:KuppenP J KPJ,
pubmed-author:SparidansR WRW,
pubmed-author:TijlF G JFG,
pubmed-author:TollenaarR A E MRA,
pubmed-author:VahrmeijerA LAL,
pubmed-author:VerlaanM RMR,
pubmed-author:van IerselL B JLB,
pubmed-author:van Persijn van MeertenE LEL,
pubmed-author:van de VeldeC J HCJ
|
| pubmed:issnType |
Print
|
| pubmed:volume |
33
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
874-81
|
| pubmed:meshHeading |
pubmed-meshheading:17400422-Adult,
pubmed-meshheading:17400422-Aged,
pubmed-meshheading:17400422-Antineoplastic Agents, Alkylating,
pubmed-meshheading:17400422-Colorectal Neoplasms,
pubmed-meshheading:17400422-Dose-Response Relationship, Drug,
pubmed-meshheading:17400422-Female,
pubmed-meshheading:17400422-Follow-Up Studies,
pubmed-meshheading:17400422-Hepatic Artery,
pubmed-meshheading:17400422-Humans,
pubmed-meshheading:17400422-Infusion Pumps,
pubmed-meshheading:17400422-Infusions, Intra-Arterial,
pubmed-meshheading:17400422-Liver Neoplasms,
pubmed-meshheading:17400422-Male,
pubmed-meshheading:17400422-Melphalan,
pubmed-meshheading:17400422-Middle Aged,
pubmed-meshheading:17400422-Netherlands,
pubmed-meshheading:17400422-Perfusion,
pubmed-meshheading:17400422-Retrospective Studies,
pubmed-meshheading:17400422-Survival Rate,
pubmed-meshheading:17400422-Treatment Outcome
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Hepatic artery infusion of high-dose melphalan at reduced flow during isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: a clinical and pharmacologic evaluation.
|
| pubmed:affiliation |
Department of Clinical Oncology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
|
| pubmed:publicationType |
Journal Article
|